Ready to improve your ICU knowledge? Check out ICU Trials for iPhone and Android, a pocket reference for 70+ landmark critical care trials, including NINDS.
Summary of the NINDS Trial
In patients presenting within 3 hours of ischemic stroke, alteplase improved 3-month neurological function (NNT=9) but did not impact 24-hour symptoms or mortality. In patients receiving alteplase, approximately one-quarter had minor bleeding, and 6.4% had symptomatic ICH (NNH=17).